Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for MaxCyte, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$1.20+1.7%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Company outlook: revenue of about $34.5M for Fiscal year 2026 — up 4.5% on a year earlier, slower than the 48.7% just reported